Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorobutanol + hexetidine
- Development stage
- Phase 4
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
- Administration
- Topical, Oral
01
Overview
Chlorobutanol + hexetidine is a combination drug used primarily for treating sore throat and oral mucositis. Hexetidine provides pronounced antibacterial activity against both gram-positive and gram-negative microorganisms, effective against aerobic and anaerobic bacteria. It has a moderate bacteriostatic effect on aerobic strains and a strong bactericidal effect on anaerobic strains. Its mechanism is based on competition with thiamine, which is necessary for microorganism growth. Chlorobutanol contributes analgesic (local anesthetic) properties to the combination, helping to reduce pain and discomfort associated with sore throat.
- Brand names
- Angilor
Beyond the preview
Go deeper on chlorobutanol + hexetidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorobutanol + hexetidine.